<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: To compare the risk of <z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">cardiovascular disease</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e>) <z:hpo ids='HP_0011420'>death</z:hpo> and the impact of <z:hpo ids='HP_0003074'>hyperglycemia</z:hpo> on the risk of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e> mortality associated with type 1 <z:mp ids='MP_0002055'>diabetes</z:mp> to that associated with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>RESEARCH DESIGN AND METHODS: The study comprised 173 participants with type 1 <z:mp ids='MP_0002055'>diabetes</z:mp>, 834 participants with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, and 1,294 nondiabetic participants, aged 45-64 years at baseline and free of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>The <z:hpo ids='HP_0011007'>age of onset</z:hpo> of <z:mp ids='MP_0002055'>diabetes</z:mp> was &gt;30 years in both diabetic groups </plain></SENT>
<SENT sid="3" pm="."><plain>RESULTS: During an 18-year follow-up, 86 participants with type 1 <z:mp ids='MP_0002055'>diabetes</z:mp>, 567 participants with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, and 252 nondiabetic participants died </plain></SENT>
<SENT sid="4" pm="."><plain><z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e> mortality rates per 1,000 person-years were 23.1 (95% CI 16.9-31.9) in type 1 diabetic, 35.3 (30.8-40.4) in type 2 diabetic, and 4.6 (3.8-5.7) in nondiabetic participants </plain></SENT>
<SENT sid="5" pm="."><plain>Adjusted hazard ratios for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e> mortality in participants with type 1 <z:mp ids='MP_0002055'>diabetes</z:mp> versus no <z:mp ids='MP_0002055'>diabetes</z:mp> was 3.6 (95% CI 2.2-5.7) in men and 13.3 (6.9-22.5) in women and in participants with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> versus no <z:mp ids='MP_0002055'>diabetes</z:mp> 3.3 (2.5-4.5) in men and 10.1 (6.7-17.4) in women </plain></SENT>
<SENT sid="6" pm="."><plain>An increment of 1 unit (%) of GHb increased <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e> mortality by 52.5% (95% CI 28.4-81.3) in type 1 diabetic subjects and by 7.5% (4.3-10.8) in type 2 diabetic participants </plain></SENT>
<SENT sid="7" pm="."><plain>CONCLUSIONS: The impact of type 1 and type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> on <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e> mortality was similar </plain></SENT>
<SENT sid="8" pm="."><plain>The effect of increasing <z:hpo ids='HP_0003074'>hyperglycemia</z:hpo> on the risk of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e> mortality was more profound in type 1 than in type 2 diabetic subjects </plain></SENT>
</text></document>